LLY-507 is a potent and selective inhibitor of the protein methyltransferase SMYD2, which plays a role in regulating various cellular processes, including gene expression and protein function. Its primary application lies in cancer research, where it is used to study the role of SMYD2 in tumor growth and progression. By inhibiting SMYD2, LLY-507 helps researchers understand its impact on cancer cell proliferation and survival, potentially leading to the development of targeted cancer therapies. Additionally, it is utilized in biochemical assays to explore the broader biological functions of SMYD2 in cellular signaling pathways and epigenetic regulation.